Cisplatin is one of the most widely used agents in cancer chemotherapy. It cross-links DNA, which can kill cells. But which part of the genome is more affected, and which is less affected? A Chinese team have now set up a universal, genome-wide assay to detect the specific cisplatin action sites. In the journal Angewandte Chemie they report initial results, which support the notion that the mitochondrial genome is one of cisplatin's main targets.
- Angewandte Chemie International Edition